attribut sg 70 vandopløseligt granulat
bayer a/s - propoxycarbazon-na, propoxycarbazon - vandopløseligt granulat - 700 g/kg propoxycarbazone-na; (~ 663 g/kg propoxycarbazon
bacara special 340 sc suspensionskoncentrat
bayer a/s - flufenacet, diflufenican, flurtamon - suspensionskoncentrat - 80 g/l flufenacet; 200 g/l diflufenican; 60 g/l flurtamon
dff-super flydende middel
bayer a/s - pyraflufen, diflufenican - flydende middel - 36 g/l pyraflufen; 500 g/l diflufenican
maister od od-formulering
bayer a/s - foramsulfuron, iodosulfuron-methyl-na, iodosulfuron, isoxadifen-ethyl, isoxadifen - od-formulering - 30 g/l foramsulfuron; 1 g/l iodosulfuron-methyl-na; (~ 0,932 g/l iodosulfuron; 30 g/l isoxadifen-ethyl; (~ 27,2 g/l isoxadifen
raft 800 wg vanddispergerbart granulat
bayer a/s - oxadiargyl - vanddispergerbart granulat - 800 g/kg oxadiargyl
yrc2894 od-formulering
bayer a/s - thiacloprid - od-formulering - 240 g/l thiacloprid
bay f77 flydende bejdse
bayer a/s - penflufen - flydende bejdse - 50 g/l penflufen
ultomiris
alexion europe sas - ravulizumab - hemoglobinuri, paroxysmal - selektive immunosuppressiva - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
tavneos
vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - immunosuppressiva - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).
kefamycin vet. intramammær salve
pharmaxim sweden ab - bacitracin, benzylpenicillinkalium, neomycin - intramammær salve - kvæg